Drug Information

Drug General Information
Drug ID
D02FYE
Former ID
DIB009405
Drug Name
TT-223
Synonyms
E1-INT; GLP1-INT; Islet cell neogenesis therapy, Transition Therapeutics; Islet neogenesis therapy, Transition; Diabetes therapy, Waratah/MGH; EGF-INT, Transition Therapeutics; Glucagon-like peptide + gastrin analog, Transition; INT (diabetes), Waratah/MGH; Epidermal growth factor analog + TT-223 (diabetes), Transition; Islet neogenesis therapy (GLP-1, gastrin), Transition; Glucagon-like peptide + TT-223, (diabetes) Transition
Indication Type 1 diabetes [ICD9: 250; ICD10:E10] Phase 2 [522421]
Company
Waratah Pharmaceuticals Inc
Target and Pathway
Target(s) Gastrin/cholecystokinin type B receptor Target Info Modulator [525743]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gastric acid secretion
PANTHER Pathway CCKR signaling map ST
PathWhiz Pathway Gastric Acid Production
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
Gastrin-CREB signalling pathway via PKC and MAPK
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Secretion of Hydrochloric Acid in Parietal Cells
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 522421ClinicalTrials.gov (NCT00743002) A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione. U.S. National Institutes of Health.
Ref 525743The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.